CRBU
Income statement / Annual
Last year (2024), Caribou Biosciences, Inc.'s total revenue was $9.99 M,
a decrease of 71.01% from the previous year.
In 2024, Caribou Biosciences, Inc.'s net income was -$149.11 M.
See Caribou Biosciences, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$9.99 M |
$34.48 M |
$13.85 M |
$9.60 M |
$12.36 M |
$5.79 M |
| Cost of Revenue |
$0.00
|
$112.08 M
|
$3.64 M
|
$984.00 K
|
$34.43 M
|
$23.64 M
|
| Gross Profit |
$6.07 M
|
-$77.60 M
|
$10.21 M
|
$8.61 M
|
-$22.06 M
|
-$17.85 M
|
| Gross Profit Ratio |
0.61
|
-2.25
|
0.74
|
0.9
|
-1.78
|
-3.08
|
| Research and Development Expenses |
$130.15 M
|
$112.08 M
|
$82.23 M
|
$52.26 M
|
$34.43 M
|
$23.64 M
|
| General & Administrative Expenses |
$46.46 M
|
$38.46 M
|
$38.02 M
|
$24.32 M
|
$14.06 M
|
$16.46 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$46.46 M
|
$38.46 M
|
$38.02 M
|
$24.32 M
|
$14.06 M
|
$16.46 M
|
| Other Expenses |
$0.00
|
$0.00
|
$7.18 M
|
-$1.35 M
|
$514.00 K
|
$0.00
|
| Operating Expenses |
$176.61 M
|
$150.54 M
|
$120.25 M
|
$76.58 M
|
$48.49 M
|
$40.09 M
|
| Cost And Expenses |
$176.61 M
|
$150.54 M
|
$120.25 M
|
$76.58 M
|
$48.49 M
|
$40.09 M
|
| Interest Income |
$0.00
|
$10.70 M
|
$4.60 M
|
$148.00 K
|
$236.00 K
|
$1.05 M
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$8.00 K
|
$20.00 K
|
$4.00 K
|
| Depreciation & Amortization |
$0.00
|
$3.53 M
|
$3.64 M
|
$984.00 K
|
$900.00 K
|
$751.00 K
|
| EBITDA |
-$166.62 M |
-$112.53 M |
-$104.78 M |
-$66.00 M |
-$35.21 M |
-$30.21 M |
| EBITDA Ratio |
-16.67
|
-3.26
|
-7.56
|
-6.88
|
-2.85
|
-5.22
|
| Operating Income Ratio |
-16.67
|
-3.37
|
-7.68
|
-6.98
|
-2.92
|
-5.93
|
| Total Other Income/Expenses Net |
$17.50 M
|
$14.18 M
|
$7.05 M
|
$377.00 K
|
-$3.00 K
|
$3.34 M
|
| Income Before Tax |
-$149.11 M
|
-$101.88 M
|
-$99.35 M
|
-$66.60 M
|
-$36.13 M
|
-$30.97 M
|
| Income Before Tax Ratio |
-14.92
|
-2.95
|
-7.17
|
-6.94
|
-2.92
|
-5.35
|
| Income Tax Expense |
-$9.00 K
|
$193.00 K
|
$70.00 K
|
$321.00 K
|
-$1.82 M
|
-$7.54 M
|
| Net Income |
-$149.11 M
|
-$102.07 M
|
-$99.42 M
|
-$66.92 M
|
-$34.31 M
|
-$23.43 M
|
| Net Income Ratio |
-14.92
|
-2.96
|
-7.18
|
-6.97
|
-2.78
|
-4.05
|
| EPS |
-1.65 |
-1.38 |
-1.64 |
-1.11 |
-1.24 |
-0.85 |
| EPS Diluted |
-1.65 |
-1.38 |
-1.64 |
-1.11 |
-1.24 |
-0.85 |
| Weighted Average Shares Out |
$90.32 M
|
$73.81 M
|
$60.80 M
|
$60.26 M
|
$27.66 M
|
$27.66 M
|
| Weighted Average Shares Out Diluted |
$90.32 M
|
$73.81 M
|
$60.80 M
|
$60.26 M
|
$27.66 M
|
$27.66 M
|
| Link |
|
|
|
|
|
|
